Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Cefepime-induced Neurotoxicity: A Retrospective Cohort Study in a South-Indian Tertiary Healthcare Facility

Author(s): Erfan Alijani, Sonal Sekhar Miraj*, Shilia Jacob Kurian, Mahadev Rao and Kavitha Saravu

Volume 18, Issue 1, 2023

Published on: 20 May, 2022

Page: [69 - 78] Pages: 10

DOI: 10.2174/1574886317666220309090408

Price: $65

conference banner
Abstract

Background: Cefepime is a fourth-generation cephalosporin with a broad spectrum coverage and anti-pseudomonal activity. The safety profile of cefepime was relatively favourable until neurotoxicity was first reported in 1999. Despite cefepime-induced neurotoxicity (CIN), it continues to be a principal part of parenteral treatment for various infections.

Objective: The study aimed to determine the incidence and risk factors for CIN compared to other antibiotics.

Methods: A retrospective cohort study was conducted involving 738 patients over eight months in Kasturba Medical College and Hospital, Manipal, India. Patients with cefepime were selected as study cohort (SC; n= 496), and other antibiotics were included in the reference cohort (RC; n=242).

Results: The results showed that 53 (10.7%) patients developed neurotoxicity in the SC, whereas 12 (5%) patients in the RC. A significant association was found between neurotoxicity and cefepime use (X2 =6.641; p=0.01). SC has a 2.29 times increased risk of neurotoxicity than RC (OR: 2.29; 95% CI: 1.2-4.38). Risk estimation showed that renal failure patients had a 5.5 times higher risk for CIN than non-renal failure patients (OR: 5.5; 95% CI: 2.98 - 10.17). CIN symptoms were disorientation (38.5%), loss of consciousness (23.1%), drowsiness (18.5%), etc. The calculated number needed to harm (NNH) for cefepime was 17.2.

Conclusion: The study found a higher incidence of CIN compared to other antibiotics-induced neurotoxicity and a harmful association between cefepime use and CIN development. Besides, renal failure is a risk factor for CIN. Therefore, the study warrants the use of cefepime, where no other alternatives are available.

Keywords: Adverse effects, antibiotics, cefepime, drug safety, neurotoxicity, neurotoxic effects.

« Previous Next »
Graphical Abstract

[1]
Bazan JA, Martin SI, Kaye KM. Newer beta-lactam antibiotics: Doripenem, ceftobiprole, ceftaroline, and cefepime. Infect Dis Clin North Am 2009; 23(4): 983-996 ix..
[http://dx.doi.org/10.1016/j.idc.2009.06.007] [PMID: 19909894]
[2]
Wong KM, Chan WK, Chan YH, Li CS. Cefepime-related neurotoxicity in a haemodialysis patient. Nephrol Dial Transplant 1999; 14(9): 2265-6.
[http://dx.doi.org/10.1093/ndt/14.9.2265] [PMID: 10489256]
[3]
Sugimoto M, Uchida I, Mashimo T, et al. Evidence for the involvement of GABA(A) receptor blockade in convulsions induced by cephalosporins. Neuropharmacology 2003; 45(3): 304-14.
[http://dx.doi.org/10.1016/S0028-3908(03)00188-6] [PMID: 12871648]
[4]
Grill MF, Maganti R. Cephalosporin-induced neurotoxicity: Clinical manifestations, potential pathogenic mechanisms, and the role of electroencephalographic monitoring. Ann Pharmacother 2008; 42(12): 1843-50.
[http://dx.doi.org/10.1345/aph.1L307] [PMID: 19033476]
[5]
Roncon-Albuquerque R Jr, Pires I, Martins R, Real R, Sousa G, von Hafe P. Ceftriaxone-induced acute reversible encephalopathy in a patient treated for a urinary tract infection. Neth J Med 2009; 67(2): 72-5.
[PMID: 19299850]
[6]
Bresson J, Paugam-Burtz C, Josserand J, Bardin C, Mantz J, Pease S. Cefepime overdosage with neurotoxicity recovered by high-volume haemofiltration. J Antimicrob Chemother 2008; 62(4): 849-50.
[http://dx.doi.org/10.1093/jac/dkn256] [PMID: 18565972]
[7]
Capparelli FJ, Diaz MF, Hlavnika A, Wainsztein NA, Leiguarda R, Del Castillo ME. Cefepime- and cefixime-induced encephalopathy in a patient with normal renal function. Neurology 2005; 65(11): 1840.
[http://dx.doi.org/10.1212/01.wnl.0000187079.12413.6a] [PMID: 16344542]
[8]
Chatellier D, Jourdain M, Mangalaboyi J, et al. Cefepime-induced neurotoxicity: An underestimated complication of antibiotherapy in patients with acute renal failure. Intensive Care Med 2002; 28(2): 214-7.
[http://dx.doi.org/10.1007/s00134-001-1170-9] [PMID: 11907668]
[9]
Garces EO, Andrade de Anzambuja MF, da Silva D, Bragatti JA, Jacoby T, Saldanha Thomé F. Renal failure is a risk factor for cefepime-induced encephalopathy. J Nephrol 2008; 21(4): 526-34.
[PMID: 18651542]
[10]
Jallon P, Fankhauser L, Du Pasquier R, et al. Severe but reversible encephalopathy associated with cefepime. Neurophysiol Clin 2000; 30(6): 383-6.
[http://dx.doi.org/10.1016/S0987-7053(00)00234-3] [PMID: 11191931]
[11]
Lam S, Gomolin IH. Cefepime neurotoxicity: Case report, pharmacokinetic considerations, and literature review. Pharmacotherapy 2006; 26(8): 1169-74.
[http://dx.doi.org/10.1592/phco.26.8.1169] [PMID: 16863493]
[12]
Maganti R, Jolin D, Rishi D, Biswas A. Nonconvulsive status epilepticus due to cefepime in a patient with normal renal function. Epilepsy Behav 2006; 8(1): 312-4.
[http://dx.doi.org/10.1016/j.yebeh.2005.09.010] [PMID: 16278098]
[13]
Plensa E, Gallardo E, Ribera JM, Batlle M, Oriol A, Costa J. Nonconvulsive status epilepticus associated with cefepime in a patient undergoing autologous stem cell transplantation. Bone Marrow Transplant 2004; 33(1): 119-20.
[http://dx.doi.org/10.1038/sj.bmt.1704314] [PMID: 14704665]
[14]
Sonck J, Laureys G, Verbeelen D. The neurotoxicity and safety of treatment with cefepime in patients with renal failure. Nephrol Dial Transplant 2008; 23(3): 966-70.
[http://dx.doi.org/10.1093/ndt/gfm713] [PMID: 18175786]
[15]
Barr J, Fraser GL, Puntillo K, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med 2013; 41(1): 263-306.
[http://dx.doi.org/10.1097/CCM.0b013e3182783b72] [PMID: 23269131]
[16]
Fugate JE, Kalimullah EA, Hocker SE, Clark SL, Wijdicks EF, Rabinstein AA. Cefepime neurotoxicity in the intensive care unit: A cause of severe, underappreciated encephalopathy. Crit Care 2013; 17(6): R264.
[http://dx.doi.org/10.1186/cc13094] [PMID: 24200036]
[17]
Appa AA, Jain R, Rakita RM, Hakimian S, Pottinger PS. Characterizing cefepime neurotoxicity: A systemic review. Open Forum Infect Dis 2017; 4(4)ofx170
[http://dx.doi.org/10.1093/ofid/ofx170] [PMID: 29071284]
[18]
Payne LE, Gagnon DJ, Riker RR, et al. Cefepime-induced neurotoxicity: A systematic review. Crit Care 2017; 21(1): 276.
[http://dx.doi.org/10.1186/s13054-017-1856-1] [PMID: 29137682]
[19]
Lamoth F, Buclin T, Pascual A, et al. High cefepime plasma concentrations and neurological toxicity in febrile neutropenic patients with mild impairment of renal function. Antimicrob Agents Chemother 2010; 54(10): 4360-7.
[http://dx.doi.org/10.1128/AAC.01595-08] [PMID: 20625153]
[20]
Flaatten H, de Lange DW, Artigas A, et al. The status of intensive care medicine research and a future agenda for very old patients in the ICU. Intensive Care Med 2017; 43(9): 1319-28.
[http://dx.doi.org/10.1007/s00134-017-4718-z] [PMID: 28238055]
[21]
Giardina C, Cutroneo PM, Mocciaro E, et al. Adverse drug reactions in hospitalized patients: Results of the FORWARD (Facilitation of Reporting in Hospital Ward) study. Front Pharmacol 2018; 9: 350.
[http://dx.doi.org/10.3389/fphar.2018.00350] [PMID: 29695966]
[22]
Lee SJ. Cefepime-induced neurotoxicity. J Neurocrit Care 2019; 12(2): 74-84.
[http://dx.doi.org/10.18700/jnc.190109]
[23]
Fishman RA. Blood-brain and CSF barriers to penicillin and related organic acids. Arch Neurol 1966; 15(2): 113-24.
[http://dx.doi.org/10.1001/archneur.1966.00470140003001] [PMID: 5945968]
[24]
Gangireddy VG, Mitchell LC, Coleman T. Cefepime neurotoxicity despite renal adjusted dosing. Scand J Infect Dis 2011; 43(10): 827-9.
[http://dx.doi.org/10.3109/00365548.2011.581308] [PMID: 21604923]

Rights & Permissions Print Cite
Article Metrics
5
© 2024 Bentham Science Publishers | Privacy Policy